Biocon Limited — JV/Acquisition, 29-06-2026: Acquisition

Biocon now fully owns Biocon Biologics (BBL), acquiring the remaining shares to make it a wholly-owned subsidiary. This Rs. 330.78 Cr deal involved a share swap, with Biocon issuing 87.86 lakh new equity shares to selling shareholders. This strategic move consolidates Biocon's control over BBL, simplifying its corporate structure and enhancing operational synergies. Key impacts include full integration of BBL's financials and a modest Rs. 4.39 Cr increase in Biocon's paid-up equity capital due to the share allotment. Notably, there's no cash outflow for Biocon.